Colorectal Cancer

Results from the INNATE trial showed the use of sotigalimab to be a safe and efficacious regimen for patients with rectal cancer.

The fixed-dose combination of favezelimab and pembrolizumab did not show an improvement in overall survival compared with the standard of care in patients with metastatic CRC.

The approval is based on results from the global phase 3 FRESCO-2 trial, which demonstrated improvement in OS in patients with refractory metastatic colorectal cancer.

NO-CUT trial data show that DRFS was maintained when non-operative management was used in patients with pMMR locally advanced rectal cancer.

Subgroup analysis in a phase 3 trial show OS benefits with the ramucirumab-based regimen in female patients and those with left-sided tumors.

Improved overall survival was also noted when atezolizumab plus bevacizumab and FOLFOXIRI were used to treat patients with pMMR tumors.

CytoDyn intends to submit its final study protocol to the FDA, engage a clinical research organization, and complete preparatory work to initiate the phase 2 trial.

Managing high-grade squamous intraepithelial lesions may reduce the risk of anal cancer based on data from the phase 3 ANCHOR trial.

Shield, the first FDA-approved blood test for CRC screening, may offer convenient screening access for those who are at average risk for the disease.

The recommendation was made following mid-stage, end-of-phase 2 data for the botensilimab/balstilimab combination, which yielded lower responses in patients.

Key opinion leaders evaluate the selection of available assays and platforms in relation to specific clinical objectives.

Medical experts examine how recent data on circulating tumor DNA-based minimal residual disease testing may impact the clinical management and treatment of colorectal cancer.

Key opinion leaders analyze recent findings from the BESPOKE study.

The panel examines recent studies from the INTERCEPT program investigating the utility of circulating tumor DNA (ctDNA) for minimal residual disease (MRD) detection in colorectal cancer (CRC).

Jagoda Misniakiewicz, PharmD, discussed implementing fruquintinib into clinical practice and how it's mechanism of action compares with others in the space.

The key opinion leaders share their approaches for communicating about circulating tumor DNA and minimal residual disease to patients, emphasizing the significance of ctDNA testing in detecting MRD.

Experts outline circulating tumor (ct) DNA analysis, detailing the two main techniques and their respective advantages and disadvantages.

The EA2201 trial assessed nivolumab plus ipilimumab and short-course radiation therapy for patients with locally advanced rectal cancer.

HRQOL data from the CheckMate 8HW trial may further support frontline nivolumab/ipilimumab for those with MSI-H or dMMR metastatic colorectal cancer.

Arvind Dasari, MD, MS, outlines the evolution of colorectal cancer screening, addressing historical challenges, and the development of non-invasive screening techniques.

Leading experts offer insights into colorectal cancer, including its prevalence, staging, and the current landscape of treatment options.

Data from FRESCO-2 support the approval of fruquintinib for those with previously treated metastatic colorectal cancer in the European Union.

Data from the colorectal cancer cohort of the KRYSTAL-1 trial support the accelerated approval of adagrasib/cetuximab in KRAS G12C–mutated disease.

Phase 2 data show that vaccination with PolyPEPI1018 may enhance the efficacy of atezolizumab in those with microsatellite stable metastatic CRC.

The addition of liver transplant to chemotherapy in those with colorectal cancer and liver metastases boosted overall survival.

Treatment with complete mesocolic excision appears to reduce the length of hospital stay compared with conventional surgery in right colon cancer.

Investigators may continue to reevaluate the benefits of the AI navigator MyEleanor over time in other patient populations.

Determining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.

Data from the phase 3 CRC-PREVENT trial support the sensitivity of ColoSense in the detection of colorectal cancer.

CheckMate-8HW assessed the efficacy of first-line nivolumab plus ipilimumab in patients with MSI-H/dMMR metastatic colorectal cancer.